On October 22, 2026 – HUYABIO International announced positive Phase 3 results for its HDAC inhibitor HBI-8000 (tucidinostat) ...

Four-month gain in PFS with HBI-8000, 13 months in LDH-normal subgroup, but toxicity a con ...

DelveInsight's 'HDAC Inhibitor Pipeline Insight 2023' report provides comprehensive global coverage of pipeline HDAC inhibitors in various stages of clinical development, major pharmaceutical ...

A new review argues that disease-specific HDAC isoforms, not broad-spectrum inhibition, should guide epigenetic drug ...

Surveys show most men in the United States are interested in using male contraceptives, yet their options remain limited to unreliable condoms or invasive vasectomies. Recent attempts to develop drugs ...

Imagine if we could inhale scents that delay the onset of cancer, inflammation, or neurodegenerative disease. Researchers at the University of California, Riverside, are poised to bring this ...

Adenoid cystic carcinoma (ACC) is a rare malignancy of the salivary glands that typically follows an indolent yet persistent clinical course, characterized by frequent perineural invasion, local ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

HUYABIO has achieved a key "milestone," according to CEO Mireille Gillings, Ph.D., succeeding in a phase 3 trial of its oral HDAC inhibitor HBI-8000 in combination with Bristol Myers Squibb's Opdivo ...

Different prognostic value of cytokeratin-19 mRNA-positive circulating tumor cells according to estrogen receptor status in early breast cancer No significant financial relationships to disclose. This ...